These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12685522)

  • 21. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
    Childress AC; Spencer T; Lopez F; Gerstner O; Thulasiraman A; Muniz R; Post A
    J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):351-61. PubMed ID: 19702487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
    Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
    J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
    Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
    J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.
    Marchetti A; Magar R; Lau H; Murphy EL; Jensen PS; Conners CK; Findling R; Wineburg E; Carotenuto I; Einarson TR; Iskedjian M
    Clin Ther; 2001 Nov; 23(11):1904-21. PubMed ID: 11768842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
    Robinson DM; Keating GM
    Drugs; 2006; 66(5):661-8; discussion 669-70. PubMed ID: 16620143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
    Drugs R D; 2002; 3(4):279-82. PubMed ID: 12455205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
    Sugrue D; Bogner R; Ehret MJ
    Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC; Wan GJ; Kemner JE; Olfson M
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.
    Lopez F; Silva R; Pestreich L; Muniz R
    Paediatr Drugs; 2003; 5(8):545-55. PubMed ID: 12895137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.
    Teuscher NS; Sikes CR; McMahen R; Engelking D
    J Clin Psychopharmacol; 2018 Oct; 38(5):467-474. PubMed ID: 30119076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
    Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):157-159. PubMed ID: 34550957
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
    Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
    Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
    J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analog classroom assessment of Adderall in children with ADHD.
    Swanson JM; Wigal S; Greenhill LL; Browne R; Waslik B; Lerner M; Williams L; Flynn D; Agler D; Crowley K; Fineberg E; Baren M; Cantwell DP
    J Am Acad Child Adolesc Psychiatry; 1998 May; 37(5):519-26. PubMed ID: 9585654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.
    Teicher MH; Polcari A; Foley M; Valente E; McGreenery CE; Chang WW; McKay G; Midha KK
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):416-31. PubMed ID: 16958567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis.
    Sonuga-Barke EJ; Van Lier P; Swanson JM; Coghill D; Wigal S; Vandenberghe M; Hatch S
    Eur Child Adolesc Psychiatry; 2008 Jun; 17(4):245-54. PubMed ID: 18071840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.